title: GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action.
abstract: Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor cell immunotherapies have demonstrated long-lasting, and specific anti-tumor immune responses in animal models. The studies reported here specifically evaluate two aspects of the immune response generated by such immunotherapies: the persistence of irradiated tumor cells at the immunization site, and the breadth of the immune response elicited to tumor associated antigens (TAA) derived from the immunotherapy. To further define the mechanism of GM-CSF-secreting cancer immunotherapies, immunohistochemistry studies were performed using the B16F10 melanoma tumor model. In contrast to previous reports, our data revealed that the irradiated tumor cells persisted and secreted high levels of GM-CSF at the injection site for more than 21 days. Furthermore, dense infiltrates of dendritic cells were observed only in mice treated with GM-CSF-secreting B16F10 cells, and not in mice treated with unmodified B16F10 cells with or without concurrent injection of rGM-CSF. In addition, histological studies also revealed enhanced neutrophil and CD4+ T cell infiltration, as well as the presence of apoptotic cells, at the injection site of mice treated with GM-CSF-secreting tumor cells. To evaluate the scope of the immune response generated by GM-CSF-secreting cancer immunotherapies, several related B16 melanoma tumor cell subclones that exist as a result of genetic drift in the original cell line were used to challenge mice previously immunized with GM-CSF-secreting B16F10 cells. These studies revealed that GM-CSF-secreting cancer immunotherapies elicit T cell responses that effectively control growth of related but antigenically distinct tumors. Taken together, these studies provide important new insights into the mechanism of action of this promising novel cancer immunotherapy.
authors.affiliation: Cell Genesys Inc., 500 Forbes Blvd., South San Francisco, CA, 94080, USA, andrew.simmons@cellgenesys.com.
authors.forename: Andrew D
authors.initials: AD
authors.lastname: Simmons
authors.forename: Betty
authors.initials: B
authors.lastname: Li
authors.forename: Melissa
authors.initials: M
authors.lastname: Gonzalez-Edick
authors.forename: Carol
authors.initials: C
authors.lastname: Lin
authors.forename: Marina
authors.initials: M
authors.lastname: Moskalenko
authors.forename: Thomas
authors.initials: T
authors.lastname: Du
authors.forename: Jennifer
authors.initials: J
authors.lastname: Creson
authors.forename: Melinda J
authors.initials: MJ
authors.lastname: VanRoey
authors.forename: Karin
authors.initials: K
authors.lastname: Jooss
mesh_terms: D000818:Animals; D017209:Apoptosis; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000276:immunology; D004195:Disease Models, Animal; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008546:Melanoma, Experimental; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins; D013601:T-Lymphocytes / Q000276:immunology
chemical_list: D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor